Clinical Observation Of Jiawei Yougui Pill In Alleviating Myelosuppression After Chemotherapy For Malignant Tumor (syndrome Of Spleen And Kidney Yang Deficiency)

Objective:To observe the clinical effect of Jiawei Yougui Pill in reducing bone marrow suppression in patients with spleen kidney yang deficiency syndrome after chemotherapy.Methods:The subjects of this study were selected from the first Department of oncology,Yueyang Hospital Affiliated to Hunan University of traditional Chinese medicine from January 2020 to March 2021,72 patients met the inclusion criteria,36 cases in each group.By dynamically tracking the changes of leukocytes,neutrophils,platelets,TCM syndrome score,KPS score and other indicators in the process of treatment,the curative effect was analyzed from the incidence and degree of bone marrow suppression after chemotherapy,symptom changes,and quality of life.Results:Compared with the control group,the incidence and degree of leucopenia and neutropenia in the observation group were lower(P<0.05).There was no significant difference in thrombocytopenia between the two groups(P>0.05).The effective rate of TCM syndrome integral in the observation group was higher than that in the treatment group(P<0.05).The improvement rate of KPS score in the observation group was higher than that in the control group(P<0.05).Conclusion:Jiawei Yougui Pill is effective in reducing the incidence and degree of myelosuppression in chemotherapy patients with spleen kidney yang deficiency syndrome.It has obvious curative effect on leukopenia and neutropenia,but has no obvious curative effect on thrombocytopenia.It can improve the clinical symptoms and quality of life of patients with spleen kidney yang deficiency syndrome.